PETALING JAYA: Malaysia’s landmark decision to invoke a “government-use” licence to get access to affordable versions of a hepatitis C drug will have a major impact on global efforts to open up expensive treatments to more people, the Geneva-based Drugs for Neglected Diseases initiative (DNDi) said.
This should give 400,000 people living with hepatitis C in Malaysia access to sofosbuvir, DNDi executive director Dr Bernard Pécoul said in a statement on Wednesday.
Already a subscriber? Log in.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!